On July 29th, local time, the American Association for Clinical Chemistry (AACC) Annual Scientific Meeting & Clinical Lab Expo (ADLM 2025), a premier global event in the field of in vitro diagnostics (IVD), officially opened in Chicago. B&E with a range of innovative products, instantly attracting significant attention and numerous client inquiries on the first day of the exhibition.
At this event, B&E showcased its comprehensive, full-industry-chain solutions spanning point-of-care testing (POCT), clinical chemistry, hematology, and more. The i-Check 200 handheld blood gas analyzer and the lumiSTAT A8 was star products for emergency and critical care settings, praised for their portability and rapid testing capabilities. The electrolyte analyzer, featuring globally leading integrated biosensor technology, drew strong international interest due to its maintenance-free operation and low consumable costs. Meanwhile, the Hemax 60 five-part differential hematology analyzer and the BC 200 clinical chemistry analyzer with an integrated electrolyte module demonstrated modular flexibility, enabling "one instrument, multiple functions" to meet laboratories' demands for efficiency and integration.
On the opening day, Professor Wang Chuanxin, Chair of the Chinese Society of Laboratory Medicine (CSLM) and former President of the Second Hospital of Shandong University, visited the B&E booth with a delegation of experts, including Vice Chair Professor Guan Ming, following his keynote presentation at the conference. After a detailed examination of the products and listening to a company overview, Professor Wang remarked: "B&E has deeply integrated technologies such as integrated biosensors, microfluidics, and electrochemistry. Their product performance has reached international advanced standards. Through years of dedication to the global market, B&E has set an exemplary model for Chinese IVD companies expanding overseas."
Moving forward, B&E will further strengthen its global market presence, continuously increase investment in research and development, and leverage its agile, localized advantages and advanced technological solutions to deliver even more tailored services. The company is committed to advancing the global impact of 'Made-in-China' innovation in the healthcare sector.
